# A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve

Source: https://onco.cc/trials/nct05955508/  
OnCo record `nct05955508` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Linvoseltamab in multiple myeloma, run by Regeneron Pharmaceuticals, active and no longer recruiting.

## Summary

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma is a phase 2 interventional study registered as NCT05955508 by Regeneron Pharmaceuticals, with 40 participants enrolled, started 2024-01-30 and due to reach its primary completion in 2033-01-25. Interventions recorded: Linvoseltamab. Conditions listed: Smoldering Multiple Myeloma (SMM). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05955508
- Phase: 2
- Setting: Phase 2 Study of Linvoseltamab in Patients With Smoldering Multiple Myeloma at High Risk of Progression to Multiple Myeloma
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05955508: https://clinicaltrials.gov/study/NCT05955508

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Linvoseltamab](https://onco.cc/drugs/linvoseltamab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct05955508.json